You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中生製藥(01177.HK)鎮痛消炎藥膏獲藥監局受理上市申請
阿思達克 06-30 16:55
中生製藥(01177.HK)公布,其研發的「洛索洛芬鈉凝膠貼膏」已向中國藥監局提交上市申請並獲得受理,用於骨關節炎、肌肉痛、外傷所致腫脹疼痛,有消炎、鎮痛之效。 集團指,洛索洛芬鈉屬於苯丙酸類非甾體消炎藥,其作用機理是抑制環氧化(酉每),從而抑制花生四烯酸轉化成前列腺素,具有消炎、解熱、鎮痛的作用,其作用範圍廣,見效快,特別是鎮痛作用較強。與其他非甾體抗炎藥相比,洛索洛芬鈉為前體藥物,對胃腸道無明顯刺激作用,耐受性較好。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account